Tier 2 — strong

Association between malnutrition and hyperhomocysteine in Alzheimer's disease patients and diet intervention of betaine

Jianying Sun, Shiling Wen, Jing Zhou, Shuling Ding
Journal of clinical laboratory analysis 2017 31(5):e22090

Bibliography

PubMed
PMID 28671332
PubMed Central
PMC6817125
DOI
10.1002/jcla.22090
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized exploratory clinical intervention
ModelHuman participants
Sample97 Alzheimer patients and 65 healthy comparators
InterventionReported betaine doses 50, 100 or 200 micrograms/kg; untreated comparison
Duration1 month
EndpointsNutrition status; Homocysteine; Cognition; Inflammation

What the study showed, in plain terms

Published in 2017, this source examined brain health and combination interventions. Design: Randomized exploratory clinical intervention. Sample/model: 97 Alzheimer patients and 65 healthy comparators. The exposure or intervention was Reported betaine doses 50, 100 or 200 micrograms/kg; untreated comparison. Follow-up or treatment period: 1 month.

The report associated malnutrition with elevated homocysteine and described biochemical and cognitive improvements during betaine treatment.

Unusual reported dose units, limited allocation/masking detail and short follow-up warrant caution. This is insufficient to establish treatment of Alzheimer disease.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • The report associated malnutrition with elevated homocysteine and described biochemical and cognitive improvements during betaine treatment.
  • The recorded outcome domains were Nutrition status; Homocysteine; Cognition; Inflammation.
  • The result applies to the tested exposure: Reported betaine doses 50, 100 or 200 micrograms/kg; untreated comparison; 1 month.

What this study can and cannot tell us

  • Unusual reported dose units, limited allocation/masking detail and short follow-up warrant caution. This is insufficient to establish treatment of Alzheimer disease.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 2
A study of the treatment of Rett syndrome with folate and betaine
Daniel G Glaze et al. · Journal of child neurology · 2009
Tier 2
A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome
Julia Han et al. · Orphanet journal of rare diseases · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology